CRISPR Advances

A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point not only for this rare genetic disorder but for the broader field of genetic medicine.

Hereditary angioedema is a lifelong condition characterized by sudden and sometimes life-threatening swelling episodes, driven by excessive production of bradykinin, a molecule that increases vascular permeability. Current treatments can prevent attacks effectively, but they require ongoing injections or daily medication, placing a continuous burden on patients. The new approach aims to change that paradigm by intervening at the genetic level with a one-time therapy.

The treatment, known as lonvoguran ziclumeran, uses CRISPR technology to switch off a gene in liver cells that is responsible for producing kallikrein, a key enzyme upstream of bradykinin. By reducing kallikrein levels, the therapy addresses the root cause of the disease rather than managing its symptoms. Unlike earlier gene-editing strategies that required cells to be modified outside the body, this therapy is delivered intravenously and works directly inside the patient.

In the trial, 80 patients were randomly assigned to receive either the CRISPR therapy or a placebo. Over a follow-up period spanning several months, those who received the treatment experienced an 87 percent reduction in attack rates. Notably, nearly two-thirds of treated patients remained completely attack-free without the need for ongoing preventive therapy, compared with just over one in ten in the placebo group. The need for emergency medication dropped sharply, and patients reported meaningful improvements in daily functioning and overall quality of life.

Equally important is the safety profile observed so far. Reported side effects were generally mild and transient, including infusion-related reactions, fatigue, and headaches. No serious treatment-related adverse events were identified in the treated group. Longer-term data from earlier-phase studies suggest that the benefits of the therapy may persist for several years after a single administration, although continued monitoring will be essential to assess durability and detect any delayed risks.

The implications extend beyond hereditary angioedema. This study provides some of the strongest evidence to date that in vivo CRISPR therapies, those delivered directly into the body, can be both effective and sufficiently safe in a large, controlled clinical setting. Because the liver is a central organ for producing many circulating proteins, similar strategies could potentially be applied to a range of genetic and metabolic diseases.

Source.